C-Path and CHDI establish a consortium to expedite approval of HD therapeutics

(The Critical Path Institute (C-Path)) C-Path and CHDI are collaborating to set up a Huntington's Disease Regulatory Science Consortium (HD-RSC), bringing together participants from within and without the HD community to advance drug development tools and facilitate clinical data standardization and collaboration. 'The need for C-Path's expertise in consortium building and regulatory science has become increasingly apparent as our community sees a number of high-quality therapeutic programs approach the clinic,' says Robi Blumenstein, President of CHDI Management, Inc.
Source: EurekAlert! - Biology - Category: Biology Source Type: news